Seminars in Oncology
Volume 31, Issue 1 , Pages 1-3 , February 2004

Reduced-intensity conditioning or nonmyeloablative stem cell transplantation: introduction, rationale, and historic background

  • Shimon Slavin (Guest Editor)

      Affiliations

    • Department of Bone Marrow Transplantation and Cancer Immunotherapy, Danny Cunniff Leukemia Research Laboratory, Hadassah University Hospital, Ein Kerem, Jerusalem, Israel
    • Corresponding Author InformationAddress reprint requests to Shimon Slavin, MD, Department of Bone Marrow Transplantation and Cancer Immunotherapy, Hadassah University Hospital, Ein Kerem, Jerusalem 91120, Israel

References 

  1. Thomas ED. Marrow transplantation for malignant diseases. J Clin Oncol. 1983;1:517–531
  2. Gratwohl A, Hermans J, Goldman JM, et al.  Risk assessment for patients with chronic myeloid leukaemia before allogeneic or marrow transplantation. Chronic Leukaemia Working Party of the EBMT. Lancet. 1998;352:1087–1092
  3. Weiden PL, Sullivan KM, Fluornoy N, et al.  Antileukemic effect of chronic graft-versus-host disease (Contribution to improved survival after allogeneic marrow transplantation). N Engl J Med. 1981;304:1529–1533
  4. Weiden PL, Fluornoy N, Sanders JE, et al.  Antileukemic effect of graft-versus-host disease contributes to improved survival after allogeneic marrow transplantation. Transplantation. 1981;13:248–251
  5. Sullivan KM, Weiden PL, Storb R, et al.  Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. Blood. 1989;73:1720–1726
  6. Slavin S, Weiss L, Morecki S, et al.  Eradication of murine leukemia with histoincompatible marrow grafts in mice conditioned with total lymphoid irradiation (TLI). Cancer Immunol Immunother. 1981;11:155–161
  7. Moscovitch M, Slavin S. Anti-tumor effects of allogeneic bone marrow transplantation in (NZB x NZW)F1 hybrids with spontaneous lymphosarcoma. J Immunol. 1984;132:997–1000
  8. Slavin S, Strober S, Fuks Z, et al.  Long-term survival of skin allogafts in mice treated with fractionated total lymphoid irradiation. Science. 1976;193:1252–1254
  9. Slavin S, Strober S, Fuks Z, et al.  Induction of specific tissue transplantation tolerance using fractionated total lymphoid irradiation in adult mice (Long-term survival of allogeneic bone marrow and skin grafts). J Exp Med. 1977;146:34–48
  10. Slavin S, Fuks Z, Kaplan HS, et al.  Transplantation of allogeneic bone marrow without graft vs host disease using total lymphoid irradiation. J Exp Med. 1978;147:963–972
  11. Weiss L, Morecki S, Vitetta ES, et al.  Suppression and elimination of BCL1 leukemia by allogeneic bone marrow transplantation. J Immunol. 1983;130:2452–2455
  12. Weiss L, Lubin I, Factorowich Y, et al.  Effective graft vs leukemia effects independent of graft vs host disease after T-cell depleted allogeneic bone marrow transplantation in a murine model of B-cell leukemia/lymphoma. Role of cell therapy and rIL-2. J Immunol. 1994;153:2562–2567
  13. Raanani P, Dazzi F, Sohal J, et al.  The rate and kinetics of molecular response to donor leucocyte transfusions in chronic myeloid leukaemia patients treated for relapse after allogeneic bone marrow transplantation. Br J Haematol. 1997;99:945–950
  14. Boasberg PD, Tokita KM, Terasaki PI, et al.  Lymphocyte transfusion therapy for cancer patients. Blood. 1996;87:3522–3523
  15. Or R, Ackerstein A, Nagler A, et al.  Allogeneic cell mediated immunotherapy for breast cancer after autologous stem cell transplantation (A clinical pilot study). Cytokines Cell Mol Ther. 1998;4:1–6
  16. European Group for Bone Marrow Transplantation Slavin S, Naparstek E, Or R, et al.  Prevention of GVHD and induction of graft vs leukemia (GVL) effects (Will it ever be possible?). Bone Marrow Transplant. 1988;3(suppl 1):208–209
  17. Slavin S, Ackerstein A, Nagler A, et al.  Cell-mediated cytokine-activated immunotherapy (CCI) of malignant hematological disorders for eradication of minimal residual disease (MRD) in conjunction with conventional chemotherapy or bone marrow transplantation (BMT). Blood. 1990;76:566a; (suppl 1, abstr)
  18. Slavin S, Naparstek E, Nagler A, et al.  Allogeneic cell therapy for relapsed leukemia following bone marrow transplantation with donor peripheral blood lymphocytes. Exp Hematol. 1995;23:1553–1562
  19. Slavin S, Naparstek E, Nagler A, et al.  Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse post allogeneic bone marrow transplantation. Blood. 1996;87:2195–2204
  20. Kolb HJ, Mittermueller J, Clemm CH, et al.  Donor leukocyte transfusion for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood. 1990;76:2462–2465
  21. Kolb H, Schattenberg A, Goldman J, et al.  Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood. 1995;86:2041–2050
  22. Drobyski WR, Keever CA, Roth MS, et al.  Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation (Efficacy and toxicity of a defined T-cell dose). Blood. 1993;82:2310–2318
  23. Porter DL, Roth MS, McGarigle C, et al.  Induction of graft versus host disease for relapsed chronic myeloid leukemia. N Engl J Med. 1994;330:100–106
  24. Mackinnon S, Papadopoulos EB, Carabasi MH, et al.  Adoptive immunotherapy evaluating escalating doses of donor leukocyte for relapse of chronic myeloid leukemia after bone marrow transplantation (Separation of graft versus leukemia response from graft versus disease). Blood. 1995;86:1261–1268

PII: S0093-7754(03)00558-X

doi: 10.1053/j.seminoncol.2003.10.015

Seminars in Oncology
Volume 31, Issue 1 , Pages 1-3 , February 2004

Article Tools